Skip to content
Home » Archives for vittoria.majocchi@smm-srl.it

vittoria.majocchi@smm-srl.it

CR10049, the first intra-articular OA-targeted kinase inhibitor for the treatment of the inflammatory osteoarthritis (OA) phenotype, new preclinical data presented at the OARSI World Congress on OA

  • News

Press Release April 20, 2025 Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that… Read More »CR10049, the first intra-articular OA-targeted kinase inhibitor for the treatment of the inflammatory osteoarthritis (OA) phenotype, new preclinical data presented at the OARSI World Congress on OA

Oral presentation at the American College of Rheumatology on CR10049, the first intra-articular, long-acting Src family kinase inhibitor for the inflammatory osteoarthritis (OA) phenotype

  • News

Press Release Presentation October 10, 2025 Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that… Read More »Oral presentation at the American College of Rheumatology on CR10049, the first intra-articular, long-acting Src family kinase inhibitor for the inflammatory osteoarthritis (OA) phenotype

Phase I/II study of vorbipiprant combined with anti-PD-1 immunotherapy results in metastatic gastrointestinal non-colorectal cancers presented at ASCO 2025

  • News

Press Release Poster May 30, 2025 Monza (Italy) – Rottapharm Biotech announces that results from the phase I/II study of the EP4 antagonist vorbipiprant (CR6086) with… Read More »Phase I/II study of vorbipiprant combined with anti-PD-1 immunotherapy results in metastatic gastrointestinal non-colorectal cancers presented at ASCO 2025

Rottapharm Biotech presents recent results on CR10049, the first OA-targeted kinase inhibitor for the treatment of the inflammatory osteoarthritis (OA) phenotype, at the OARSI World Congress on OA

  • News

Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that new exciting preclinical data supporting the advancement of CR10049 (a targeted kinase inhibitor for the inflammatory OA phenotype) have been presented at the Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis, held April 24 – 27, 2025 in Incheon, South Korea

Vorbipiprant combined with PD-1 blockade for refractory microsatellite stable metastatic colorectal cancer phase I/II trial results published in Clinical Cancer Research

  • News

Press Release Online Publication December 02, 2024 Monza (Italy) – Rottapharm Biotech announces that results from the phase I/II study of the EP4 antagonist vorbipiprant… Read More »Vorbipiprant combined with PD-1 blockade for refractory microsatellite stable metastatic colorectal cancer phase I/II trial results published in Clinical Cancer Research

Updated results and subgroup analysis of the phase I/II study of CR6086 (vorbipiprant) and balstilimab in advanced colorectal cancer presented at ASCO 2024

  • News

Press Release Poster May 31, 2024 Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that… Read More »Updated results and subgroup analysis of the phase I/II study of CR6086 (vorbipiprant) and balstilimab in advanced colorectal cancer presented at ASCO 2024

Rottapharm Biotech announces upcoming oral presentation of CR10049 in the inflammatory osteoarthritis (OA) phenotype at the OARSI World Congress on OA

  • News

Press Release Presentation April 11, 2024 Monza (Italy) – Rottapharm Biotech, a research company dedicated to the discovery and development of innovative drugs, today announces that… Read More »Rottapharm Biotech announces upcoming oral presentation of CR10049 in the inflammatory osteoarthritis (OA) phenotype at the OARSI World Congress on OA

Rottapharm Biotech discloses at ESMO 2023 favourable results from the Phase 1/2 study of the EP4 receptor antagonist CR6086 combined with the anti-PD-1 balstilimab in advanced colorectal cancer

  • News

Press Release Poster October 23, 2023 Monza (Italy) – Rottapharm Biotech announces favourable clinical results of CR6086, its potent and selective small molecule antagonist of the… Read More »Rottapharm Biotech discloses at ESMO 2023 favourable results from the Phase 1/2 study of the EP4 receptor antagonist CR6086 combined with the anti-PD-1 balstilimab in advanced colorectal cancer